Re-Thinking Oncology HTAs: the (Growing) Role of Non-OS Endpoints
Re-Thinking Oncology HTAs: the (Growing) Role of Non-OS Endpoints
Published on PharmExec
Overall Survival (OS) has traditionally been the key benchmark in Health Technology Assessments (HTA) for oncology drug assessments, particularly in the case of incurable and/or metastatic diseases.
However, while OS provides a definitive and objective measure, it also carries limitations that can hinder the ability of payers to fully evaluate the therapeutic improvements of new treatments. In a recent article published on Pharmaceutical Executive, Anais Frappe and Mattia Belloni explore the role of non-OS endpoints, and advocate for a more systematic and balanced recognition of these endpoints, alongside OS, in HTAs.
About the authors
Anaïs Frappé is a Partner at Windrose Consulting Group in London, and Mattia Belloni is a Senior Engagement at Windrose Consulting Group. This article draws upon analytical work and insights provided by Windrose Consulting Group analysts, which informed its content and conclusions.
Please get in touch if you would like to discuss Oncology HTAs.